CN101238120A - 脲衍生物、它们的制备方法及其应用 - Google Patents
脲衍生物、它们的制备方法及其应用 Download PDFInfo
- Publication number
- CN101238120A CN101238120A CNA2006800145076A CN200680014507A CN101238120A CN 101238120 A CN101238120 A CN 101238120A CN A2006800145076 A CNA2006800145076 A CN A2006800145076A CN 200680014507 A CN200680014507 A CN 200680014507A CN 101238120 A CN101238120 A CN 101238120A
- Authority
- CN
- China
- Prior art keywords
- group
- alkyl
- aromatics
- base
- urea
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Treating Waste Gases (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0504360A FR2885129B1 (fr) | 2005-04-29 | 2005-04-29 | Nouveaux derives de l'ureee substituee parun thiazole ou benzothiazole, leur procede de preparation, leur application a titre de medicaments, les compositions pharmaceutiques les renfermant et utilisation. |
FR0504360 | 2005-04-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101238120A true CN101238120A (zh) | 2008-08-06 |
Family
ID=35311522
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2006800145076A Pending CN101238120A (zh) | 2005-04-29 | 2006-04-24 | 脲衍生物、它们的制备方法及其应用 |
Country Status (25)
Country | Link |
---|---|
US (2) | US8247412B2 (fr) |
EP (2) | EP1874765B1 (fr) |
JP (1) | JP4995189B2 (fr) |
KR (1) | KR20080003380A (fr) |
CN (1) | CN101238120A (fr) |
AR (1) | AR056991A1 (fr) |
AT (1) | ATE548368T1 (fr) |
AU (1) | AU2006243328B2 (fr) |
BR (1) | BRPI0611025A2 (fr) |
CA (1) | CA2605008A1 (fr) |
CR (1) | CR9469A (fr) |
CY (1) | CY1112960T1 (fr) |
DK (1) | DK1874765T3 (fr) |
EA (1) | EA200702375A1 (fr) |
ES (1) | ES2384052T3 (fr) |
FR (1) | FR2885129B1 (fr) |
HR (1) | HRP20120424T1 (fr) |
IL (1) | IL186854A0 (fr) |
NO (1) | NO20076145L (fr) |
PL (1) | PL1874765T3 (fr) |
PT (1) | PT1874765E (fr) |
TW (1) | TW200714598A (fr) |
UY (1) | UY29510A1 (fr) |
WO (1) | WO2006117211A2 (fr) |
ZA (1) | ZA200708871B (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106946851A (zh) * | 2017-03-14 | 2017-07-14 | 牡丹江医学院 | 一种用于预防和治疗肾结石的药物 |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2885129B1 (fr) | 2005-04-29 | 2007-06-15 | Proskelia Sas | Nouveaux derives de l'ureee substituee parun thiazole ou benzothiazole, leur procede de preparation, leur application a titre de medicaments, les compositions pharmaceutiques les renfermant et utilisation. |
US7875609B2 (en) | 2005-11-25 | 2011-01-25 | Galapagos Sasu | Urea derivatives, processes for their preparation, their use as medicaments, and pharmaceutical compositions containing them |
CA2648939C (fr) | 2006-04-20 | 2014-07-08 | Amgen Inc. | Formules d'emulsions stables |
GB0613674D0 (en) * | 2006-07-10 | 2006-08-16 | Proskelia Sas | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor |
AU2008233088B2 (en) | 2007-03-30 | 2013-09-26 | Amgen Inc. | Calcimimetic compounds for use in the treatment of bowel disorders |
JP5321452B2 (ja) * | 2007-05-08 | 2013-10-23 | 味の素株式会社 | 下痢の予防又は治療剤 |
AU2008275595B2 (en) * | 2007-07-10 | 2013-11-14 | Amgen Inc. | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor |
WO2010104882A1 (fr) | 2009-03-10 | 2010-09-16 | Amgen Inc. | Procédés de modulation de la motilité des spermatozoïdes |
WO2013138753A1 (fr) | 2012-03-16 | 2013-09-19 | Fox Chase Chemical Diversity Center, Inc. | Promédicaments de riluzole et leur méthode d'utilisation |
CN105492444B (zh) | 2013-07-02 | 2018-09-07 | 百时美施贵宝公司 | 作为rock抑制剂的三环吡啶-甲酰胺衍生物 |
JP6522602B2 (ja) | 2013-07-02 | 2019-05-29 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Rock阻害剤としての三環式ピリド−カルボキサミド誘導体 |
HUE058204T2 (hu) * | 2015-03-03 | 2022-07-28 | Biohaven Therapeutics Ltd | Riluzol prodrugok és felhasználásuk |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL31574A0 (en) | 1968-02-13 | 1969-04-30 | Ciba Ltd | Use of certain ureas for combating weeds |
US3897242A (en) | 1968-02-13 | 1975-07-29 | Ciba Geigy Ag | Use of 1-(3-chloro-4-methylphenyl)-3,3-dimethylurea in wheat and barley crops |
JPS58109464A (ja) | 1981-12-23 | 1983-06-29 | Nippon Paint Co Ltd | アミノ酸化合物、その製法ならびに触媒 |
US4579947A (en) | 1983-06-16 | 1986-04-01 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted phenylalkylpiperazinylpropyl (ureas or thioureas) useful for treatment of immunological, inflammatory and allergic disorder |
US4521583A (en) | 1984-02-09 | 1985-06-04 | American Cyanamid Company | Curable epoxy resin compositions |
US4594373A (en) | 1984-02-09 | 1986-06-10 | American Cyanamid Company | Curable epoxy resin compositions |
FR2601363B1 (fr) * | 1986-07-08 | 1988-10-21 | Synthelabo | (dimethylamino)-2 ethyl) ((((methylthio)-2 phenyl) (phenylmethyl)amino)-2 oxo-2 ethyl) carbamates ou urees, leur preparation et leur application en therapeutique. |
US5242947A (en) | 1988-02-10 | 1993-09-07 | New York University | Use of polyamines as ionic-channel regulating agents |
US5227397A (en) | 1989-04-28 | 1993-07-13 | Pfizer Inc. | Polyamines and polypeptides useful as antagonists of excitatory amino acid neuro-transmitters and/or as blockers of calcium channels |
DD298412A5 (de) | 1989-04-28 | 1992-02-20 | ������@���Kk�� | Verfahren zur herstellung von polypeptiden, die geeignet sind als antagonisten exzitatorischer aminosaeure-neurotransmitter und/oder blocker der calciumkanaele |
EP0597830A1 (fr) | 1989-07-03 | 1994-05-25 | New York University Nyu Medical Center | Emploi de polyamines en tant qu'agents regulateurs de canaux ioniques |
US5153226A (en) | 1989-08-31 | 1992-10-06 | Warner-Lambert Company | Acat inhibitors for treating hypocholesterolemia |
DE69132423T2 (de) | 1990-11-19 | 2001-04-26 | Monsanto Co., St. Louis | Inhibitoren retroviraler Proteasen |
US5312928A (en) | 1991-02-11 | 1994-05-17 | Cambridge Neuroscience | Calcium channel antagonists and methodology for their identification |
US6031003A (en) | 1991-08-23 | 2000-02-29 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
ES2218531T3 (es) | 1991-08-23 | 2004-11-16 | Nps Pharmaceuticals, Inc. | Arilalquilaminas activas sobre los receptores del calcio. |
US6011068A (en) | 1991-08-23 | 2000-01-04 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
US6313146B1 (en) | 1991-08-23 | 2001-11-06 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
EP0641333B1 (fr) | 1992-05-20 | 1996-08-14 | G.D. Searle & Co. | Procede de production d'intermediaires utiles dans la synthese d'inhibiteurs de proteases retrovirales |
DE69334250D1 (de) | 1992-12-29 | 2009-01-29 | Abbott Lab | Verfahren und Intermediate zur Herstellung von retroviralen Proteasehemmern |
JPH0841006A (ja) | 1994-08-05 | 1996-02-13 | Nisshin Flour Milling Co Ltd | ジウレア誘導体 |
PT1203761E (pt) | 1994-10-21 | 2005-04-29 | Nps Pharma Inc | Compostos activos do receptor de calcio |
ES2145929T3 (es) | 1994-11-04 | 2000-07-16 | Santen Pharmaceutical Co Ltd | Nuevo derivado de 1,3-dialquil-urea que tiene un grupo hidroxilo. |
EP0798291B1 (fr) | 1994-12-14 | 2002-09-11 | Santen Pharmaceutical Co., Ltd. | Nouveaux derives 1,3-dialkyluree |
JP3306571B2 (ja) | 1995-06-28 | 2002-07-24 | 参天製薬株式会社 | エンドセリン変換酵素阻害剤 |
JPH10195037A (ja) | 1996-02-15 | 1998-07-28 | Tanabe Seiyaku Co Ltd | フェノール誘導体 |
CA2197364A1 (fr) | 1996-02-15 | 1997-08-16 | Toshikazu Suzuki | Compose phenolique et methode de preparation |
CN1254465C (zh) | 1996-04-09 | 2006-05-03 | Nps医药公司 | 钙代谢化合物 |
WO1999007672A1 (fr) | 1997-08-05 | 1999-02-18 | Novo Nordisk A/S | Derivees d'anilines 2,5- et 3,5-disubstituees, leur preparation et utilisation |
JPH11139969A (ja) | 1997-08-07 | 1999-05-25 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
CA2284864A1 (fr) | 1998-01-21 | 1999-07-29 | Zymogenetics, Inc. | Dialkylurees utilisees en tant que substances imitant la calcitonine |
AU779089B2 (en) | 1999-04-15 | 2005-01-06 | Bristol-Myers Squibb Holdings Ireland Unlimited Company | Cyclic protein tyrosine kinase inhibitors |
US6365617B1 (en) * | 1999-06-29 | 2002-04-02 | Ortho-Mcneil Pharmaceutical, Inc. | Indole and indazole urea-peptoids as thrombin receptor antagonists |
FR2809396B1 (fr) | 2000-05-24 | 2005-10-14 | Centre Nat Rech Scient | Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation |
FR2812875B1 (fr) | 2000-08-08 | 2003-12-12 | Centre Nat Rech Scient | Nouvelles diamines possedant une activite modulatrice des casr et leur mode de preparation |
FR2820136A1 (fr) * | 2001-01-26 | 2002-08-02 | Aventis Pharma Sa | Nouveaux derives de l'uree, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation |
US6598746B2 (en) * | 2001-09-13 | 2003-07-29 | Washburn Graphics, Inc. | Display carton having an internally reinforced hanger panel |
US20040082588A1 (en) | 2002-09-30 | 2004-04-29 | Schering Corporation | Methods for treating disorders of calcium homeostasis |
JP2005336173A (ja) * | 2004-04-27 | 2005-12-08 | Santen Pharmaceut Co Ltd | 骨粗鬆症治療剤 |
EP1757582B1 (fr) | 2004-05-28 | 2015-12-30 | Mitsubishi Tanabe Pharma Corporation | Arylalkylamines et procédé pour la production de celles-ci |
FR2885129B1 (fr) | 2005-04-29 | 2007-06-15 | Proskelia Sas | Nouveaux derives de l'ureee substituee parun thiazole ou benzothiazole, leur procede de preparation, leur application a titre de medicaments, les compositions pharmaceutiques les renfermant et utilisation. |
EP1882684B1 (fr) | 2005-05-19 | 2014-12-10 | Astellas Pharma Inc. | Derive de pyrrolidine ou son sel |
US7875609B2 (en) | 2005-11-25 | 2011-01-25 | Galapagos Sasu | Urea derivatives, processes for their preparation, their use as medicaments, and pharmaceutical compositions containing them |
GB0613674D0 (en) | 2006-07-10 | 2006-08-16 | Proskelia Sas | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor |
AU2008275595B2 (en) | 2007-07-10 | 2013-11-14 | Amgen Inc. | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor |
-
2005
- 2005-04-29 FR FR0504360A patent/FR2885129B1/fr not_active Expired - Fee Related
-
2006
- 2006-04-24 AU AU2006243328A patent/AU2006243328B2/en not_active Ceased
- 2006-04-24 EA EA200702375A patent/EA200702375A1/ru unknown
- 2006-04-24 BR BRPI0611025A patent/BRPI0611025A2/pt not_active IP Right Cessation
- 2006-04-24 EP EP06724709A patent/EP1874765B1/fr active Active
- 2006-04-24 AT AT06724709T patent/ATE548368T1/de active
- 2006-04-24 US US11/919,537 patent/US8247412B2/en not_active Expired - Fee Related
- 2006-04-24 DK DK06724709.8T patent/DK1874765T3/da active
- 2006-04-24 JP JP2008508167A patent/JP4995189B2/ja not_active Expired - Fee Related
- 2006-04-24 CN CNA2006800145076A patent/CN101238120A/zh active Pending
- 2006-04-24 ES ES06724709T patent/ES2384052T3/es active Active
- 2006-04-24 KR KR1020077024941A patent/KR20080003380A/ko not_active Application Discontinuation
- 2006-04-24 CA CA002605008A patent/CA2605008A1/fr not_active Abandoned
- 2006-04-24 WO PCT/EP2006/004166 patent/WO2006117211A2/fr active Application Filing
- 2006-04-24 PL PL06724709T patent/PL1874765T3/pl unknown
- 2006-04-24 PT PT06724709T patent/PT1874765E/pt unknown
- 2006-04-24 EP EP11002964A patent/EP2354137A1/fr not_active Withdrawn
- 2006-04-26 TW TW095114960A patent/TW200714598A/zh unknown
- 2006-04-26 AR ARP060101666A patent/AR056991A1/es unknown
- 2006-04-28 UY UY29510A patent/UY29510A1/es not_active Application Discontinuation
-
2007
- 2007-10-16 ZA ZA200708871A patent/ZA200708871B/xx unknown
- 2007-10-23 CR CR9469A patent/CR9469A/es unknown
- 2007-10-23 IL IL186854A patent/IL186854A0/en unknown
- 2007-11-28 NO NO20076145A patent/NO20076145L/no not_active Application Discontinuation
-
2012
- 2012-05-17 HR HRP20120424TT patent/HRP20120424T1/hr unknown
- 2012-06-06 CY CY20121100508T patent/CY1112960T1/el unknown
- 2012-06-27 US US13/535,198 patent/US20120283255A1/en not_active Abandoned
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106946851A (zh) * | 2017-03-14 | 2017-07-14 | 牡丹江医学院 | 一种用于预防和治疗肾结石的药物 |
Also Published As
Publication number | Publication date |
---|---|
TW200714598A (en) | 2007-04-16 |
CR9469A (es) | 2008-03-06 |
ZA200708871B (en) | 2009-03-25 |
PL1874765T3 (pl) | 2012-08-31 |
JP2008539186A (ja) | 2008-11-13 |
UY29510A1 (es) | 2006-12-29 |
CA2605008A1 (fr) | 2006-11-09 |
JP4995189B2 (ja) | 2012-08-08 |
PT1874765E (pt) | 2012-05-25 |
DK1874765T3 (da) | 2012-06-18 |
HRP20120424T1 (hr) | 2012-06-30 |
EP1874765B1 (fr) | 2012-03-07 |
AU2006243328A1 (en) | 2006-11-09 |
AU2006243328B2 (en) | 2011-09-08 |
FR2885129A1 (fr) | 2006-11-03 |
BRPI0611025A2 (pt) | 2016-11-16 |
EP1874765A2 (fr) | 2008-01-09 |
US20120283255A1 (en) | 2012-11-08 |
EA200702375A1 (ru) | 2008-06-30 |
US8247412B2 (en) | 2012-08-21 |
EP2354137A1 (fr) | 2011-08-10 |
KR20080003380A (ko) | 2008-01-07 |
NO20076145L (no) | 2008-01-28 |
ES2384052T3 (es) | 2012-06-28 |
ATE548368T1 (de) | 2012-03-15 |
FR2885129B1 (fr) | 2007-06-15 |
CY1112960T1 (el) | 2016-04-13 |
IL186854A0 (en) | 2008-02-09 |
US20100240889A1 (en) | 2010-09-23 |
AR056991A1 (es) | 2007-11-07 |
WO2006117211A2 (fr) | 2006-11-09 |
WO2006117211A3 (fr) | 2007-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101238120A (zh) | 脲衍生物、它们的制备方法及其应用 | |
RU2479577C2 (ru) | Гетероциклические соединения в качестве положительных модуляторов метаботропного глутаматного рецептора 2 (рецептора mglu2) | |
TWI432430B (zh) | 苯磺醯胺噻唑及噁唑化合物 | |
AU2006297089B2 (en) | Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors | |
AU2019283921A1 (en) | Indole carboxamide compounds useful as kinase inhibitors | |
JP2022110130A (ja) | 新規の阻害剤 | |
CN102659774A (zh) | 作为p2x3拮抗剂的哌啶和哌嗪衍生物 | |
MXPA02010651A (es) | Moduladores de receptor activado de proliferador de peroxisoma-gamma. | |
WO2010024903A1 (fr) | Benzo[d]oxazoles et benzo[d]thiazoles comme inhibiteurs de la kinase | |
PL209822B1 (pl) | Pochodna chinoliny lub chinazoliny, zawierająca ją kompozycja farmaceutyczna i zastosowanie | |
WO2008064054A2 (fr) | Composés qui modulent le récepteur cb2 | |
JP2009536613A (ja) | Cb2受容体を調節する化合物 | |
JPWO2010035727A1 (ja) | 新規ピロリノン誘導体およびそれを含有する医薬組成物 | |
CN101466714A (zh) | 作为hm74a激动剂的嘌呤酮衍生物 | |
CN111526877B (zh) | 用于ire1抑制的化合物和组合物 | |
AU2006316705B2 (en) | Urea derivatives useful as calcium receptor modulators | |
TW201805282A (zh) | 化合物及其於降低尿酸位準之用途 | |
WO2006004776A1 (fr) | Composés de 4-pyrimidineamine et leurs utilisations en tant qu’agent anti-prolifération | |
JP6559894B2 (ja) | ナトリウムチャネル遮断剤 | |
CA3166597A1 (fr) | Antagonistes du recepteur muscarinique 4 et procedes d'utilisation | |
CN104903311A (zh) | 作为lrrk2抑制剂的氨基吡啶衍生的化合物 | |
CN101374813A (zh) | 作为ppar调节剂的芳基磺酰胺和磺酰基化合物及治疗代谢性病症的方法 | |
WO2012134233A2 (fr) | Dérivé de sulfamide possédant un groupe adamantyle et un sel pharmaceutiquement acceptable de celui-ci | |
KR101586714B1 (ko) | 피라졸 화합물 | |
CN101421258B (zh) | 作为ppar调节剂的磺酰基取代的双环化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20080806 |